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ThiazolidesOriginally developed and commercialized as an antiprotozoal agent, nitazoxanide was later identiﬁed as a
ﬁrst-in-class broad-spectrum antiviral drug and has been repurposed for the treatment of inﬂuenza. A
Phase 2b/3 clinical trial recently published in The Lancet Infectious Diseases found that oral administration
of nitazoxanide 600 mg twice daily for ﬁve days reduced the duration of clinical symptoms and reduced
viral shedding compared to placebo in persons with laboratory-conﬁrmed inﬂuenza. The same study also
suggested a potential beneﬁt for subjects with inﬂuenza-like illness who did not have inﬂuenza or other
documented respiratory viral infection. From a chemical perspective, nitazoxanide is the scaffold for a
new class of drugs called thiazolides. These small-molecule drugs target host-regulated processes
involved in viral replication. Nitazoxanide is orally bioavailable and safe with extensive post-marketing
experience involving more than 75 million adults and children. A new dosage formulation of nitazoxa-
nide is presently undergoing global Phase 3 clinical development for the treatment of inﬂuenza. Nitazox-
anide inhibits a broad range of inﬂuenza A and B viruses including inﬂuenza A(pH1N1) and the avian
A(H7N9) as well as viruses that are resistant to neuraminidase inhibitors. It is synergistic with neuramin-
idase inhibitors, and combination therapy with oseltamivir is being studied in humans as part of ongoing
Phase 3 clinical development. Nitazoxanide also inhibits the replication of a broad range of other RNA and
DNA viruses including respiratory syncytial virus, parainﬂuenza, coronavirus, rotavirus, norovirus, hepa-
titis B, hepatitis C, dengue, yellow fever, Japanese encephalitis virus and human immunodeﬁciency virus
in cell culture assays. Clinical trials have indicated a potential role for thiazolides in treating rotavirus and
norovirus gastroenteritis and chronic hepatitis B and chronic hepatitis C. Ongoing and future clinical
development is focused on viral respiratory infections, viral gastroenteritis and emerging infections such
as dengue fever.
 2014 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Fig. 1. Chemical structures of nitazoxanide, tizoxanide and RM-5038.1. Introduction
In recent years, the desirability of new broad-spectrum antiviral
drugs has been emphasized as a means of providing greater protec-
tion against a range of viruses while mitigating risks of resistance
and reducing costs associated with developing drugs that are tar-
geted to every speciﬁc virus (Shaw, 2011; Diarmond and Farzan,
2013; Debing et al., 2013; Zhou and Simmons, 2012). In view of
the constant threat caused by new emerging strains of inﬂuenza
and limitations of existing drugs, there is a particular need for
drugs with new mechanisms of action that may be used alone or
in combination with neuraminidase inhibitors to provide more
optimal medical countermeasures against seasonal and pandemic
inﬂuenza. In this context, the repurposing of nitazoxanide as a
treatment of inﬂuenza could prove to be important.
Nitazoxanide or 2-(acetyloxy)-N-(5-nitro-2-thiazolyl) benzam-
ide (Fig. 1) was ﬁrst synthesized in the early 1970s on the scaffold
of niclosamide in replacing one benzene ring, a 6-membered ring
heterocycle, by a nitrothiazole, a 5-membered ring heterocycle
(Rossignol and Cavier, 1975). Initially, nitazoxanide was developed
as an oral anti-parasitic agent and studied for activity against pro-
tozoan and helminthic infections in vitro and/or in vivo in mice,
cats, dogs and sheep (Cavier and Rossignol, 1982; Euzeby et al.,
1980). It was ﬁrst studied in humans for treatment of intestinal
cestodes (Rossignol and Maisonneuve, 1984). Later, nitazoxanide
was found effective in cell culture assays and in several animal
models against the emerging intracellular protozoan, Cryptospori-
dium parvum (Blagburn et al., 1998; Theodos et al., 1998; Li
et al., 2003; Baishanbo et al., 2006), and it was licensed in the Uni-
ted States (Alinia, Romark Laboratories) as an Orphan Drug for
treatment of diarrhea caused by C. parvum and Giardia intestinalis
in adults and children at least 12 months of age (Ortiz et al.,
2001; Amadi et al., 2002; Rossignol et al., 2001). It is the ﬁrst
and remains as the only FDA-approved treatment for Cryptosporidi-
um infection. Nitazoxanide has also been widely commercialized in
Latin America and in India where it is indicated for treating a broad
spectrum of intestinal parasitic infections.
In addition to its antiparasitic activity, nitazoxanide and its
active circulating metabolite, tizoxanide (Fig. 1; Rossignol and
Stachulski, 1999), are active in vitro against a broad range of obli-
gate and facultative anaerobic gram positive and gram negative
bacteria (Dubreuil et al., 1996; Mégraud et al., 1998; Pankuch
and Appelbaum, 2006; Hecht et al., 2007; Finegold et al., 2009;
Freeman et al., 2011) as well as replicating and non-replicating
strains of Mycobacterium tuberculosis (De Carvalho et al., 2009).
Animal studies and randomized clinical trials have conﬁrmed the
activity of the drug in treating Clostridium difﬁcile disease (McVay
and Rolfe, 2000; Musher et al., 2006, 2009). Hoffman et al. (2007)
studied the mechanism of action of nitazoxanide against anaerobic
bacteria and protozoa and showed that nitazoxanide inhibits pyru-
vate:ferredoxin oxidoreductase (PFOR) enzyme-dependent
electron transfer reactions that are essential for anaerobic energy
metabolism. Studies in M. tuberculosis have shown that nitazoxa-nide acts as an uncoupler disrupting membrane potential and
intra-organism pH homeostasis (De Carvalho et al., 2011).
Having been licensed in the United States, nitazoxanide was
subjected to extensive pharmacological testing for safety in ani-
mals and humans (Romark Laboratories, 2007). Recently, a clinical
trial to evaluate cardiac safety in humans showed no effect on car-
diac repolarization (Taubel et al., 2014). It is estimated that more
than 75 million adults and children have been exposed to nitazox-
anide in post-marketing experience for treating intestinal parasitic
infections without any signiﬁcant drug-related safety issues.
In clinical trials and post-marketing experience, nitazoxanide
has been used primarily for treating intestinal infections. Treating
systemic infections in animal models and in humans has been
challenging because of the very poor solubility of the drug and
its short elimination half-life. Following oral administration, nita-
zoxanide active pharmaceutical ingredient is absorbed from the
intestinal tract and rapidly hydrolyzed by plasma esterases to form
tizoxanide, its active circulating metabolite, which then is glucur-
ono-conjugated in the liver. The drug is eliminated in urine and
bile as tizoxanide and tizoxanide glucuronide. The half-life of
tizoxanide in plasma is only approximately 1.3 h. More than
99.9% of circulating tizoxanide is bound to plasma proteins
(Broekhuysen et al., 2000; Romark Laboratories, 2007).
Table 1
In vitro studies of tizoxanide against respiratory viruses.
Strain Cell line EC50 (lg/mL) SI1 Reference
Orthomyxoviridae: inﬂuenza A and B
H1N1 A/Puerto Rico/8/34 MDCK 0.3 >50 Rossignol et al. (2009a,b)
Monocytic U937 0.3 >50 Rossignol et al. (2009a,b)
T-lymphocytic Jurkat 0.3 >50 Rossignol et al. (2009a,b)
Alveolar type II-like A549 0.3 >50
H1N1 A/Wisconsin/33 MDCK 0.5 >100 Rossignol et al. (2009a,b)
H1N1 A/Parma/24/09 (oseltamivir-R) MDCK 0.4 >125 Belardo et al. (2011)
H1N1 A/Goose/Italy/29624603 MDCK 1.5 >33 Belardo et al. (2011)
H1N1 A/California/04/p2009 MDCK <0.34 Sleeman et al. (2014)
H3N2v A/Ohio/88/2012 MDCK <0.27 Sleeman et al. (2014)
H3N2v A/Ohio/83/2012 MDCK <1.75 Sleeman et al. (2014)
H3N2 A/Washington/01/2007 MDCK <0.5 Sleeman et al. (2014)
H3N2 A/Texas/12/2007 MDCK <0.72 Sleeman et al. (2014)
H3N2 A/Firenze/7/03 MDCK 1.0 >50 Belardo et al. (2011)
H3N2 A/Parma/6/07 (amantadine-R) MDCK 0.3 >166 Belardo et al. (2011)
H3N8 A/Canine/Colorado-1/224986/06 MDCK 0.2 644 Ashton et al. (2010)
H3N8 A/Canine/Colorado-3/3/06 MDCK 0.2 751 Ashton et al. (2010)
H3N8 A/Canine/Colorado-4/2025974/07 MDCK 0.2 374 Ashton et al. (2010)
H5N9 A/Chicken/Italy/9097/97 MDCK 0.5 >100 Rossignol et al. (2009a,b)
H7N1 A/Turkey/Italy/RA5563/99 MDCK 1.5 >33 Belardo et al. (2011)
Inﬂuenza B/Parma/3/04 MDCK 0.9 >55 Rossignol et al. (2009a,b)
Paramyxoviridae
Parainﬂuenza Sendai virus (SeV) 37RC 0.5 >100 Rossignol and Santoro, (2014)
Respiratory syncytial virus (RSV) A-2 HeLa ATCC 0.3 >166 Rossignol and Santoro, (2014)
Coronaviridae
Canine coronavirus S-378 (CCoV) A72 1.0 >50 Rossignol and Santoro, (2014)
Picornavirdae
Human rhinovirus type 2 HeLa R19 >50 Rossignol and Santoro, (2014)
1 Selectivity index (IC50/50% cytotoxic concentration).
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antiviral activity of nitazoxanide, rounding out a remarkably broad
spectrum of activity for this drug and prompting efforts to develop
nitazoxanide and other thiazolides as a new class of antiviral
agents. A new controlled-release pharmaceutical formulation of
nitazoxanide was developed to deliver drug systemically, and the
drug is being repurposed as a new broad-spectrum agent with a
novel mechanism of action for treatment of inﬂuenza. Here we
review the antiviral activity of nitazoxanide and other thiazolides
as reported in cell culture assays, animal studies and human clin-
ical trials with an emphasis on inﬂuenza.2. Inﬂuenza and other respiratory viruses
2.1. In vitro studies
Tizoxanide, the active circulating metabolite of nitazoxanide,
inhibited replication of 16 strains of inﬂuenza A/H1N1, H3N2,
H3N2v, H3N8, H5N9, H7N1, and one strain of inﬂuenza B (Table 1).
The inﬂuenza viruses were sensitive to tizoxanide (IC50s ranging
from 0.2 to 1.5 lg/mL, Table 1) using single step virus growth with
high multiplicity of infection (5 PFU/cell) and multistep virus
growth with lowmultiplicity of infection (0.001 PFU/cell). Antiviral
activity was determined after 24 h in single step assays and after
24, 48 and 72 h for the multi-step assays by 50% tissue culture
infectious dose (TCID50) and/or by hemagglutination assay. The
IC50s for tizoxanide were similar when inﬂuenza A/H1N1/PR8
was cultured in different canine and human cell lines: MDCK cells,
monocytic U937, T-lymphocytic Jurkat, and alveolar type II-like
A549 (Rossignol et al., 2009a; Ashton et al., 2010; Belardo et al.,
2011; Sleeman et al., 2014; Gubareva et al., 2014). Combinations
of nitazoxanide with oseltamivir or zanamivir are synergistic when
tested against inﬂuenza A/H1N1-PR8 and the avian A/H5N9. Com-
bination index values ranged between 0.39 and 0.63, independent
of multiplicity of infection used (Belardo et al., 2011). As observedfor the hepatitis C virus (Korba et al., 2008b), tizoxanide had a high
barrier to resistance to the inﬂuenza A virus. No decreased sensi-
tivity was observed when viruses were passaged for 30 days in
increasing concentrations (0.25, 0.50, 0.75 and 1.0 lg/mL) of tizox-
anide (Belardo et al., 2011).
Tizoxanide also inhibited replication of parainﬂuenza Sendai
virus (IC50 0.1 lg/mL), respiratory syncytial virus A2 (IC50 0.3 lg/
mL), and canine coronavirus S-378 (IC50 1 lg/mL). The drug did
not show activity in vitro against human rhinovirus type 2
(Table 1).
Peak and trough plasma concentrations of tizoxanide were
4.6 lg/mL and 0.8 lg/mL, respectively, during twice daily dosing
of nitazoxanide controlled release tablets in a Phase 2b/3 clinical
trial (Hafﬁzulla et al., 2014). These concentrations are suitable for
treating viral respiratory infections caused by inﬂuenza and other
viruses as in vitro IC50s are typically between 0.1 and 1 lg/mL.2.2. Mechanism of action
Studies of the mechanism of action of nitazoxanide against
inﬂuenza viruses have shown that the drug blocks maturation of
the viral hemagglutinin at the post-translational stage (Rossignol
et al., 2009a). The drug had no effect on the other glycoprotein,
neuraminidase, the target of oseltamivir and zanamivir, or the
M2 protein, the target of amantadine, and it had no effect on viral
infectivity, adsorption or entry into target cells (La Frazia et al.,
2013; Rossignol et al., 2009a; Shi et al., 2014).
In peripheral blood mononuclear cells (PBMCs) stimulated by
inﬂuenza virus, nitazoxanide potentiates the production of type 1
interferons (alpha and beta) produced by the host’s ﬁbroblasts
(Clerici et al., 2011). The signiﬁcance of this activity is not fully
understood, but it could contribute to the antiviral activity of nita-
zoxanide by interfering with maturation of the hemagglutinin gly-
coprotein or as another secondary mechanism of action.
Number Experiencing Symptoms (at Risk) at Each Timepoint 
0 1 2 3 4 5 6 7 8 9 10 
Placebo 87 83 81 74 61 38 21 11 8 4 4 
300 mg NTZ 89 87 83 68 52 36 24 12 7 6 5 
600 mg NTZ 79 76 70 55 36 21 14 8 7 6 5 
All three groups P=0.0178
600 mg NTZ vs. Placebo P=0.0074 
600 mg NTZ 
300 mg NTZ 
Placebo
Fig. 2. Kaplan–Meier plot of time from ﬁrst dose to alleviation of symptoms for subjects with conﬁrmed inﬂuenza enrolled in a Phase 2b/3 clinical trial of nitazoxanide in
subjects with uncomplicated inﬂuenza-like illness (Hafﬁzulla et al., 2014, reprinted with permission from Elsevier).
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A Phase 2b/3 randomized, double-blind, placebo-controlled
clinical trial was conducted in the United States to evaluate the
safety and efﬁcacy of nitazoxanide 300 mg controlled-release tab-
lets in adults and adolescents at least 12 years of age with acute
uncomplicated inﬂuenza. 624 subjects with fever, at least one
respiratory symptom and one constitutional symptom of inﬂuenza
were enrolled within 48 h of symptom onset and randomly
assigned to receive treatment with placebo, 300 mg nitazoxanide
or 600 mg nitazoxanide twice daily for ﬁve days. The primary efﬁ-
cacy analysis was time from ﬁrst dose to alleviation of symptoms
for subjects with laboratory-conﬁrmed inﬂuenza at baseline.
Subjects receiving nitazoxanide experienced shorter times to
alleviation of symptoms (600 mg: median 95.5 h, 95% CI 84.0 to
108.0, p = 0.008; 300 mg: median 109.1 h, 95% CI 96.1 to 129.5,
p = 0.521) than subjects receiving the placebo (median: 116.7 h,
95% CI 108.1 to 122.1) (Fig. 2). The lack of statistical signiﬁcance
at the 0.05 level for the low dose group may have been due to lack
of statistical power (Hafﬁzulla et al., 2014).
Inﬂuenza-infected subjects receiving nitazoxanide 600 mg also
showed signiﬁcant reductions (p = 0.0006) in TCID50 viral titers
during treatment compared to subjects receiving placebo (Fig 3).
No resistance was observed for inﬂuenza viruses collected from
nitazoxanide-treated subjects, and no adverse effect on humoral
immune response was observed. Adverse events were similar for
the three treatment groups (Table 2) (Hafﬁzulla et al., 2014).
Responses were similar for subjects infected with inﬂuenza A
and inﬂuenza B. In contrast to neuraminidase inhibitors, treatment
with nitazoxanide also signiﬁcantly reduced the duration of ﬂu-
like symptoms (17.3 h reduction in time to alleviation of symp-toms for 600 mg vs. placebo, p = 0.0208) in subjects with unknown
viral etiology (Hafﬁzulla et al., 2014).
This Phase 2b/3 clinical trial was designed according to current
FDA guidance for the development of new drugs for treating inﬂu-
enza. From a regulatory perspective, placebo-controlled trials are
required to clearly demonstrate drug-effect, and because of ethical
considerations, placebo-controlled trials cannot be conducted in
subjects with complicated illness or those at risk of complications.
The trial design was generally consistent with previous clinical tri-
als of oseltamivir and zanamivir, and while it is inherently difﬁcult
to compare results of this trial to clinical trials of neuraminidase
inhibitors conducted ﬁfteen to twenty years ago, reductions in
symptom duration for the 600 mg dose group compared to the pla-
cebo (21.2 h) were in the range of those observed during similar
trials of the neuraminidase inhibitors. Magnitude of treatment
effect observed in different clinical trials could be inﬂuenced by
study design (e.g., populations selected for analysis, use of acet-
aminophen or other symptom relief medications) and by charac-
teristics of circulating inﬂuenza strains (e.g., pathogenicity, drug
susceptibility) during a given trial. For example, this Phase 2b/3
trial enrolled subjects within 48 h of onset of symptoms while
studies of the neuraminidase inhibitors typically enrolled subjects
within 36 h of symptom onset. In subjects enrolled within 36 h of
symptom onset, the median improvement in time to symptom
alleviation for the nitazoxanide 600 mg treatment group was
extended to 26.3 h.
2.4. Global Phase 3 clinical trial
A large global Phase 3 clinical trial is being conducted to
support licensure of the nitazoxanide 300 mg controlled-release
Mean Change (95% CI) in Viral Titer 
Days after 1st dose Placebo (n=41) 300 mg NTZ (n=33) 600 mg NTZ (n=39) 
1 -0.03 (-0.61 to 0.55) -0.58 (-1.10 to -0.07) -1.11 (-1.69 to -0.52) 
2 -1.21 (-0.98 to -0.43) -1.26 (-1.96 to -0.56) -1.84 (-2.46 to -1.22) 
3 -1.65 (-2.31 to -1.00) -1.86 (-2.58 to -1.15) -2.58 (-3.03 to -2.12) 
4 -2.41 (-3.02 to -1.79) -2.46 (-3.15 to -1.77) -2.55 (-3.06 to -2.04) 
6 -2.79 (-3.40 to -2.18) -2.82 (-3.41 to -2.18) -3.01 (-3.48 to -2.54) 
Fig. 3. Mean change in inﬂuenza TCID50 viral titer from baseline during Phase 2b/3 clinical trial in patients with uncomplicated inﬂuenza-like illness. Analysis of change in
TCID50 viral titer for subjects with conﬁrmed inﬂuenza that participated from whom daily nasopharyngeal swabs were collected. Statistical comparison using mixed model
for repeated measures including baseline viral titer, treatment group and geographic location: p = 0.0006 for the difference between nitazoxanide 600 mg and placebo,
p = 0.1553 for the difference between nitazoxanide 300 mg and placebo (Hafﬁzulla et al., 2014, reprinted with permission from Elsevier).
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at ClinicalTrials.gov, number NCT01227421). Approximately 2000
subjects with inﬂuenza symptoms are being randomized to one
of four treatment arms: placebo, nitazoxanide 600 mg, oseltamivir
75 mg, or nitazoxanide 600 mg plus oseltamivir 75 mg twice daily
for ﬁve days. The primary efﬁcacy endpoint is time from ﬁrst dose
to alleviation of symptoms, and co-primary efﬁcacy analyses will
compare time from ﬁrst dose to alleviation of symptoms (i) for
the nitazoxanide 600 mg group to that of the placebo group and
(ii) for the nitazoxanide 600 mg plus oseltamivir 75 mg group to
that of each of the other (monotherapy or placebo) groups. This
study is being conducted under contract from the U.S. Department
of Health and Human Services administered by the Biomedical
Advanced Research and Development Authority (BARDA). This
study is expected to provide important information related to the
clinical beneﬁt of nitazoxanide in treating uncomplicated inﬂuenza
as well as the potential beneﬁt of combining the drug with osel-
tamivir. To date, approximately 1600 subjects have been included
in the trial over three ﬂu seasons (one Northern Hemisphere and
two Southern Hemisphere), and it is expected to be completed dur-
ing the 2014/2015 inﬂuenza season in the Northern Hemisphere.
Notably, the Phase 3 trial will be the largest clinical trial ever con-
ducted for treatment of acute uncomplicated inﬂuenza, the ﬁrst
licensure-enabling clinical trial of a combination of drugs for treat-
ing inﬂuenza, and the ﬁrst new registration-style clinical trial of
oseltamivir that has been conducted in more than ten years.
Future clinical trials of nitazoxanide are expected to include
patients at risk of inﬂuenza complications including those with
co-morbidities such as asthma, chronic obstructive pulmonary dis-
ease (COPD) or diabetes, patients over 65 years of age and children
under 12 years of age. A clinical trial in hospitalized patients withsevere acute respiratory infection (SARI) has recently been initi-
ated under the sponsorship the National Institute of Allergy and
Infectious Diseases, National Institutes of Health (registered at
ClinicalTrials.gov, number NCT02057757).3. Other viral infections
3.1. Viral gastroenteritis caused by rotavirus and norovirus
3.1.1. In vitro studies
The activity of tizoxanide has been studied using eight strains of
rotavirus cultured in three different cell lines (Table 3). Most of the
work in molecular virology was carried out with two strains of
rotavirus, the simian strain SA11-G3P(2) and the human strain
Wa-G1P(8). Antiviral activity was observed using single-step virus
growth at high m.o.i. (10 PFU/cell) and multi-step virus growth at a
low m.o.i. (0.001 PFU/cell). In a single step virus growth assay
using monkey kidney MA104 cells, tizoxanide inhibited replication
of the simian SA11-G3P(2) and the humanWa-G1P(8) with IC50s of
0.5 and 1 lg/mL, respectively, while in a multistep assay, IC50s of
0.3 lg/mL were recorded for both viruses. 50% cytotoxic concen-
trations (CC50) in these cell lines were >50 lg/mL. Similar results
were obtained using human gut-derived Caco-2 and HT-29 cells
and with human G1, G2, G3, G4, G8 and G9 strains of the virus.
Treatment of MA104 cells with 10 lg/mL of tizoxanide 3, 6 or 9 h
before infection with rotavirus did not protect the cells from viral
entry. Tizoxanide inhibited viral replication when cells were trea-
ted up to 6 h post-infection with optimal activity observed when
tizoxanide was introduced between 0 and 3 h post-infection. (La
Frazia et al., 2013; Rossignol et al., 2006).
Table 2
Most common adverse events (>1% in any treatment group) reported in Phase 2b/3 clinical trial involving subjects with acute uncomplicated inﬂuenza-like illness (Hafﬁzulla
et al., 2014, reprinted with permission from Elsevier).
Adverse event (no. and % of subjects reporting) Placebo (n = 212) Nitazoxanide 300 mg (n = 201) Nitazoxanide 600 mg (n = 211)
Diarrhea 7 (3%) 4 (2%) 17 (8%)
Headache 24 (11%) 12 (6%) 17 (8%)
Bronchitis 3 (1%) 10 (5%) 7 (3%)
Oropharyngeal pain 7 (3%) 5 (2%) 10 (5%)
Abdominal pain 7 (3%) 4 (2%) 8 (4%)
Vomiting 2 (1%) 3 (1%) 8 (4%)
Chromaturia – 6 (3%) 8 (4%)
Cough 8 (4%) 5 (2%) 8 (4%)
Sinusitis 8 (4%) 6 (3%) 3 (1%)
Nausea 6 (3%) 1 (<1%) 6 (3%)
Pyrexia 5 (2%) 4 (2%) 6 (3%)
Rhinorrhea 7 (3%) 5 (2%) 4 (2%)
LFT abnormal 4 (2%) 5 (2%) 5 (2%)
Wheezing 3 (1%) 2 (1%) 5 (2%)
Nasal congestion 5 (2%) 3 (1%) 5 (2%)
Insomnia 4 (2%) – 5 (2%)
Chills – 4 (2%) 1 (<1%)
Fatigue 2 (1%) 2 (1%) –
Otitis media – 4 (2%) 1 (<1%)
Dyspnea 3 (1%) 2 (1%) 4 (2%)
Ear pain 3 (1%) 2 (1%) 3 (1%)
Musculoskeletal stiffness 6 (3%) – 3 (1%)
Constipation – 2 (1%) –
Dry mouth – 2 (1%) 1 (<1%)
Nasopharyngitis – 2 (1%) 1 (<1%)
Blood triglycerides increase – 2 (1%) –
Lipase increase 2 (1%) 2 (1%) 1 (<1%)
Poor quality sleep – 2 (1%) –
Respiratory tract congestion – 2 (1%) –
Night sweats 1 (<1%) 2 (1%) –
Table 3
In vitro studies of tizoxanide against a broad spectrum of non-respiratory viruses.
Strain Cell line IC50 (lg/mL) SI1 Reference
Flavividae
Hepatitis C virus (HCV) Genotype 1a AVA52 0.09 56 Korba et al. (2008a)3
Hepatitis C virus (HCV) Genotype 2a Huh7.52 0.06 100 Korba et al. (2008a)3
Dengue fever virus-2 (New Guinea strain) Vero cells 0.1 10 Meneses et al. (2013)
Japanese encephalitis virus (JEV) BHK-21 0.12 155 Shi et al. (2014)4
Yellow fever virus 17DD Vero Cells 0.06 35 Meneses et al. (2013)
Hepadnaviridae
Hepatitis B virus (HBV) 2.2.15 0.06 >172 Korba et al. (2008a)3
Retroviridae
Human immunodeﬁciency virus (HIV) PBMC 0.5 >100 Tan et al., 20125
Reoviridae
Simian rotavirus A/SA11G3P{2} MA104 0.3 >100 La Frazia et al. (2013)6
Human rotavirus G1P[8] MA104 1.0 >50 La Frazia et al. (2013)6
Caliciviridae
Norovirus HG23 0.5 10 Korba, personal communication
1 Selectivity index (IC50/50% cytotoxic concentration).
2 HCV replicon-containing cell lines.
3 Supported by NIAID contract NO1-AI-30046 to Georgetown University Medical Center.
4 Supported by the Project of International Science and Technology Cooperation (No. 2010DFB33920), the Zhejiang Provincial Natural Science Foundation (No. Y110124)
and the National Natural Science Foundation of China (No. 81371814).
5 Supported by the Damon Runyon Cancer Research Foundation (DRG 2008-09); the Charles A. King Trust, N.A., Bank of America, co-trustee; the National Natural Science
Foundation of China (31100601); the National Key Basic Research Program (2012CB316503); and the Howard Hughes Medical Institute.
6 Supported by Romark Laboratories, L.C.
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system using an HG-23 cell line were 0.5 and 1.2 lg/mL respec-
tively (Korba, personal communication).
3.1.2. Mechanism of action
Studies have shown that tizoxanide inhibits the maturation of
rotavirus viral protein 7 (VP7), a glycoprotein that forming the
outer part of the virion and one of the six structural glycoproteinsinvolved in rotavirus replication, alters viroplasm formation and
interferes with viral morphogenesis (La Frazia et al., 2013).
3.1.3. Clinical trials
Two Phase 2 randomized, double-blind, placebo-controlled
studies were conducted in two hundred (200) subjects with viral
gastroenteritis caused by rotavirus or norovirus. Fifty adults and
adolescents at least 12 years of age and 150 hospitalized children
100 J.-F. Rossignol / Antiviral Research 110 (2014) 94–103from 2 months to 11 years of age, 101 of them being from 2 to
11 months of age, were included in the two studies. Adults and
adolescents at least 12 years of age received one 500 mg nitazoxa-
nide tablet or one matching placebo tablet, twice daily for three
consecutive days. Children under 12 years of age received a
20 mg/mL suspension or matching placebo administered orally at
doses of 200 mg/10 mL (4–11 years of age), 100 mg/5 mL (1–
3 years) and 50 mg/2.5 mL (<12 months) twice daily for three days.
Nitazoxanide signiﬁcantly reduced the duration of symptoms com-
pared to placebo in adults and adolescents infected with rotavirus
(p = 0.0052) as well as subjects infected with norovirus (p = 0.0295)
(Rossignol and El-Gohary, 2006). Likewise, in children with rotavi-
rus gastroenteritis, treatment with nitazoxanide signiﬁcantly
reduced the duration of symptoms compared to the placebo
(p = 0.01) (Rossignol and El-Gohary, 2006). Another study con-
ducted in 75 children aged from 28 days to 24 months hospitalized
with rotavirus gastroenteritis also reported that nitazoxanide sig-
niﬁcantly reduced the duration of illness (Teran et al., 2009). Suc-
cessful treatment of norovirus gastroenteritis with nitazoxanide
was also reported for a 43-year-old patient with leukemia who
had received chemotherapy and hematopoietic stem cell trans-
plantation (HSCT) (Siddiq et al., 2011).
A large randomized, double-blind, placebo-controlled clinical
trial supported by the Australian National Health Medical Research
Council (NHMRC) is being conducted in 400 aboriginal children
3 months to 4 years of age hospitalized with diarrhea in the
Northern Territory of Australia where severe diarrhea is caused
by Cryptosporidium parvum, rotavirus and norovirus (registered at
ClinicalTrials.gov, number NCT02165813). Kaufman et al. (2014)
have recently identiﬁed nitazoxanide as a prospect for immediate
clinical trials in immunocompromised patients infected with
norovirus.
3.2. Hepatitis B virus
3.2.1. In vitro studies
Tizoxanide exhibited selective inhibition of intracellular HBV
and extracellular virus production in 2.2.15 cells (Table 3). IC50s
of 0.06, 0.02 and 0.38 lg/mL were recorded for tizoxanide, lamivu-
dine and adefovir dipovoxil respectively with selectivity indices
>100 (Korba et al., 2008a).
3.2.2. Clinical trials
In an open-label clinical trial, nitazoxanide was administered as
one 500 mg tablet twice daily for 12 consecutive months in twelve
adult subjects with chronic HBV; four were HBeAg-positive and
eight were HBeAg-negative. Three of the four HBeAg positive
patients became HBeAg-negative in an average of three months.
Serum HBV DNA decreased in all HBeAg-positive patients and
became negative in two of the four patients; more importantly,
one patient became HBsAg negative after having cleared serum
HBV DNA. Of the eight HBeAg-negative patients, seven became
HBV DNA negative and two of these patients also became HBsAg-
negative. These results suggest that further studies are warranted
to determine the potential of nitazoxanide to cure HBV-infected
patients (Rossignol and Keeffe, 2008).
3.3. Hepatitis C virus (HCV)
3.3.1. In vitro studies
Tizoxanide was ﬁrst tested for activity against HCV genotype 1a
in the HCV replicon-containing cell line, AVA5, and genotype 1b in
the HCV replicon-containing cell line, Huh7.5 (Table 3). For geno-
type 1a, the IC50 and IC90 were 0.09 and 0.38 lg/mL, respectively,
with a selectivity index (CC50/IC50) of 56. For genotype 1b, the
IC50 and IC90 were 0.06 and 0.31 lg/mL, respectively, with a selec-tivity index (CC50/IC50) of 100. Combinations of tizoxanide with
interferon a or with 2’C methylcytidine were synergistic (Korba
et al., 2008a). The potential for resistance of HCV to tizoxanide
was studied using an HCV genotype 1b replicon-containing cell
line, which was subjected to increasing concentrations of tizoxa-
nide for 24 consecutive weeks. HCV did not exhibit reduced sus-
ceptibility to tizoxanide, and viral genome sequencing did not
show mutations characteristic of resistance. These studies sug-
gested a host-directed mechanism of action and a high barrier to
viral resistance (Korba et al., 2008b; Yon et al., 2011).
3.3.2. Mechanism of action
Mechanistic studies of the effect of tizoxanide on replication of
hepatitis C virus in cell cultures have shown that it activates pro-
tein kinase R (PKR), an important part of innate immune response,
in cells exposed to double-stranded RNA, which in turn results in
phosphorylation of eukaryotic initiation factor 2a (eIF2-a), a gene
known to block viral replication (Rossignol et al., 2008; Elazar
et al., 2009).
More recent studies using bovine viral diarrhea virus (BVDV) as
a surrogate for HCV infection, have shown that nitazoxanide inhib-
its replication of cytopathic and non-cytopathic BVDV by a mech-
anism that is likely to involve phosphorylation of PKR and eIF2-a.
The authors also observed that nitazoxanide depletes ATP-sensi-
tive intracellular Ca2+ stores resulting in mild endoplasmic reticu-
lum (ER) stress, which disrupts N-linked glycosylation of BVDV
structural proteins (Ashiru et al., 2014).
3.3.3. Clinical trials
Two hundred and eighty one (281) subjects infected with HCV
genotype 4, three with genotype 1 and one with genotype 2, a total
of 285 subjects were treated as part of a series of three clinical tri-
als conducted in Egypt. The ﬁrst was a randomized, double-blind,
placebo-controlled clinical trial conducted in 47 treatment-naïve
adults with chronic hepatitis C genotype 4. In this study, 4 of 23
subjects (17%) receiving one nitazoxanide tablet (500 mg) twice
daily for 24 weeks experienced a sustained virologic response
(SVR) with undetectable HCV RNA in serum six months after the
end of treatment (median log10 reduction = 5.0) compared to none
of the 24 subjects (0%) in the placebo treatment group (p = 0.049)
(Rossignol et al., 2008). In a second study conducted in 120 adults
with chronic hepatitis C genotype 4, administration of one 500 mg
nitazoxanide tablet twice a day for 48 weeks with one 180 lg
injection of peginterferon alfa-2a once weekly from week 13 to
48 with or without ribavirin increased SVR rates to 79% and 72%
with and without ribavirin, respectively, compared to 50% obtained
with one weekly 180 lg injection of peginterferon alfa-2a and riba-
virin, the standard of care at that time (Rossignol et al., 2009b). In
an open-label study in 44 adults with chronic hepatitis C (40 geno-
type 4, three genotype 1, one genotype 2), 80% of the subjects
achieved SVR after treatment with nitazoxanide monotherapy for
4 weeks followed by nitazoxanide plus peginterferon alfa-2a with-
out ribavirin for 36 weeks. All four subjects with genotype 1 and 2
experienced SVR (Rossignol et al., 2010). Importantly, nitazoxanide
was well tolerated by subjects with chronic hepatitis C enrolled in
each of these three Phase 2 studies with no signiﬁcant additional
side-effects or changes in laboratory safety values other than those
caused by the combination of peginterferon alfa-2a and ribavirin
carried out monthly during treatment.
While these clinical trials indicated improved responses when
nitazoxanide was administered in combination with peginterferon
for treatment of chronic hepatitis C, development was discontin-
ued due to the development of new direct acting antiviral drugs.
Combinations of nitazoxanide or other thiazolides with direct-act-
ing antiviral drugs for treating chronic hepatitis C and/or HIV may
be a path for future development.
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encephalitis viruses
Tizoxanide has been shown to inhibit replication of three other
Flaviviridae, dengue virus type 2, Japanese encephalitis virus (JEV)
and yellow fever virus (YFV), in cell culture assays. Tizoxanide
inhibited replication of dengue-2 and YFV in Vero cells with IC50s
of 0.1 and 0.06 lg/mL, respectively and selectivity indices of 10
and 35 respectively, as shown in Table 3 (Meneses et al., 2013).
Shi et al. (2014) reported that nitazoxanide inhibits replication of
JEV in BHK-21 cells with an IC50 of 0.12 lg/mL and a selectivity
index of 155. Nitazoxanide did not directly affect viral infectivity,
adsorption or entry into target cells and was most effective when
the cells were treated 2 h post-infection with a decrease in the
antiviral activity when cells were treated at 5 and 10 h post-infec-
tion. These ﬁndings were consistent with studies using inﬂuenza
virus and rotavirus (Rossignol et al., 2009a; La Frazia et al., 2013).
In mice challenged with a lethal dose of JEV, 50, 75 and 100 mg/
kg of nitazoxanide were administered by oral gavage daily for 25
consecutive days. Mice survival was observed in 30%, 70% and
90% for the 50, 75 and 100 mg/kg/day, respectively, while
untreated mice had all died by study day 9.
3.5. Human immunodeﬁciency virus (HIV)
A publication by Tan et al. (2012) reported that nitazoxanide
and tizoxanide inhibited HIV replication with IC50s of approxi-
mately 0.5 lg/mL using a p24 enzyme-linked immunosorbent
assay (ELISA) in PBMCs. The authors described a novel drug screen-
ing method used to identify strongly efﬁcacious and synergistic
drug pairs with the overall goal of expanding current antiretroviral
repertoires. The authors reported that nitazoxanide synergizes
with known HIV drugs such as integrase inhibitors, and nucleoside
and non-nucleoside reverse transcription inhibitors, exerting its
antiviral effect post-HIV-1 entry, but before or at reverse
transcription.4. New thiazolides
A large number of thiazolides closely related to the chemical
structure of nitazoxanide have been synthesized and tested for
activity against parasites, bacteria and viruses (Stachulski et al.,
2011a, 2011b). Two compounds, nitazoxanide and RM-5038, have
been selected for complete development. RM-5038 (Fig 1) is a new
thiazolide derivative in which the nitro group on the 5-position of
the thiazole ring of its chemical structure was replaced by chloride.
RM-5038 is not active against anaerobicprotozoa andbacteria, but it
is active in cell culture and in vivo against Cryptosporidium parvum
and has shown a broad spectrum of activity against HBV and HCV
similar to nitazoxanide (Gargala et al., 2010, 2013; Korba et al.,
2008a). It is better absorbed from the gastro-intestinal tract than
nitazoxanide andbetter tolerated in animal toxicology studieswhen
administered in rats and dogs for 28 consecutive days.5. Future directions
The safety of nitazoxanide and its broad-spectrum antiviral
activity suggest a large number of alternative indications that
could be explored for clinical development.
Over the next ﬁve years, clinical development of nitazoxanide is
likely to focus primarily on viral respiratory infections. Clinical tri-
als in special populations with inﬂuenza or inﬂuenza-like illnesses
will be required to evaluate the beneﬁt of the drug in hospitalized
patients, pediatric patients and persons at risk of inﬂuenza compli-
cations. In view of the large amount of safety data for nitazoxanidein children, studies in pediatric patients under 12 years of age are
likely to proceed quickly following completion of the ongoing
Phase 3 trial. Studies in young children with inﬂuenza-like illness
are likely to enroll large numbers with RSV infection. Speciﬁc stud-
ies in children with RSV infection may also be warranted.
There is presently no approved antiviral treatment for inﬂuenza
in hospitalized patients or persons at risk of complications of ﬂu.
Furthermore, randomized controlled trials in these patient popula-
tions have proven to be difﬁcult to design and conduct due to a
number of factors including inability to use a placebo, underlying
illnesses, drug efﬁcacy, etc. If the synergistic activity of nitazoxa-
nide and oseltamivir in cell cultures is conﬁrmed by the ongoing
Phase 3 clinical trial in subjects with acute uncomplicated inﬂu-
enza, that data may suggest a path for designing and conducting
clinical trials of the combination compared to nitazoxanide mono-
therapy and oseltamivir monotherapy for treating patients hospi-
talized with inﬂuenza.
As new viral respiratory infections such as the MERS coronavi-
rus emerge, development of animal models and perhaps clinical
trials to study the activity of nitazoxanide are envisioned. Preclin-
ical studies to evaluate efﬁcacy of the drug against the MERS coro-
navirus are ongoing.
Given its history of use in treating a broad range of intestinal
infections and data from Phase 2 clinical trials in patients with
rotavirus and norovirus gastroenteritis, the rationale for additional
studies of nitazoxanide against a broader range of infectious diar-
rheal illnesses including rotavirus and norovirus is strong. A study
conducted in pediatric patients in Peru has shown that empiric
treatment of diarrheal illnesses in children from that region signif-
icantly reduced the duration of illness compared to placebo
(Rossignol et al., 2012). The ongoing study in aboriginal children
supported by the Australian NHMRC is expected to provide addi-
tional data related to its use in treating diarrheal illnesses includ-
ing viral gastroenteritis. Other similar studies may be expected in
view of the growing recognition of the importance of Cryptospori-
dium as well as rotavirus and norovirus as causes of diarrhea in
children. Studies of nitazoxanide for treatment of norovirus in
immunocompromised patients have been suggested (Kaufman
et al., 2014) and are likely in view of the need for a treatment in
this population.
Aside from the advanced development of nitazoxanide for treat-
ing viral respiratory infections and viral gastroenteritis, the emer-
gence of dengue fever and perhaps other viral diseases may
provide paths for clinical development of nitazoxanide and other
thiazolides.
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